{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T13:50:43Z","timestamp":1754488243485,"version":"3.40.5"},"reference-count":136,"publisher":"Informa UK Limited","issue":"20","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Med. Chem."],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.4155\/fmc-2022-0045","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T14:35:13Z","timestamp":1661265313000},"page":"1455-1470","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Novel Systemic Therapies for Advanced Hepatocellular Carcinoma"],"prefix":"10.1080","volume":"14","author":[{"given":"Riccardo","family":"Carloni","sequence":"first","affiliation":[{"name":"Medical Oncology\rIRCCS Azienda Ospedaliero\u2013Universitaria di Bologna\rVia Albertoni 15\rBologna\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico \u2018Don Tonino Bello\u2019\rIRCCS Istituto Tumori Giovanni Paolo II\rViale Orazio Flacco 65\rBari\r70124\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Cusmai","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico \u2018Don Tonino Bello\u2019\rIRCCS Istituto Tumori Giovanni Paolo II\rViale Orazio Flacco 65\rBari\r70124\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Palloni","sequence":"additional","affiliation":[{"name":"Medical Oncology\rIRCCS Azienda Ospedaliero\u2013Universitaria di Bologna\rVia Albertoni 15\rBologna\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-4315","authenticated-orcid":false,"given":"Alessandro Di","family":"Federico","sequence":"additional","affiliation":[{"name":"Medical Oncology\rIRCCS Azienda Ospedaliero\u2013Universitaria di Bologna\rVia Albertoni 15\rBologna\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariacristina Di","family":"Marco","sequence":"additional","affiliation":[{"name":"Medical Oncology\rIRCCS Azienda Ospedaliero\u2013Universitaria di Bologna\rVia Albertoni 15\rBologna\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Massafra","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Fisica Sanitaria\rIRCCS Istituto Tumori Giovanni Paolo II\rViale Orazio Flacco 65\rBari\r70124\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annarita","family":"Fanizzi","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Fisica Sanitaria\rIRCCS Istituto Tumori Giovanni Paolo II\rViale Orazio Flacco 65\rBari\r70124\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Palmiotti","sequence":"additional","affiliation":[{"name":"Struttura Semplice Dipartimentale di Oncologia Medica per la Presa in Carico Globale del Paziente Oncologico \u2018Don Tonino Bello\u2019\rIRCCS Istituto Tumori Giovanni Paolo II\rViale Orazio Flacco 65\rBari\r70124\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[{"name":"Medical Oncology\rIRCCS Azienda Ospedaliero\u2013Universitaria di Bologna\rVia Albertoni 15\rBologna\rItaly"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"International Agency for Research on Cancer . Cancer Today. http:\/\/gco.iarc.fr\/today\/home"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy308"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.01.022"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1499-3872(16)60097-8"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.014"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00381-6"},{"issue":"2","key":"e_1_3_2_10_1","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2007.12.037","article-title":"FDA approves sorafenib for patients with inoperable liver cancer","volume":"134","author":"Lang L","year":"2008","unstructured":"Lang L . FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology134(2), 379 (2008).","journal-title":"Gastroenterology"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32453-9"},{"key":"e_1_3_2_12_1","unstructured":"US Food and Drug Administration . FDA expands approved use of Stivarga to treat liver cancer (2020). www.fda.gov\/news-events\/press-announcements\/fda-expands-approved-use-stivarga-treat-liver-cancer"},{"key":"e_1_3_2_13_1","unstructured":"US Food and Drug Administration . FDA approves cabozantinib for hepatocellular carcinoma (2019). www.fda.gov\/drugs\/fda-approves-cabozantinib-hepatocellular-carcinoma"},{"key":"e_1_3_2_14_1","unstructured":"US Food and Drug Administration . FDA approves lenvatinib for unresectable hepatocellular carcinoma (2018). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lenvatinib-unresectable-hepatocellular-carcinoma"},{"key":"e_1_3_2_15_1","unstructured":"US Food and Drug Administration . FDA approves ramucirumab for hepatocellular carcinoma (2019). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ramucirumab-hepatocellular-carcinoma"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30207-1"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.801379"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0905"},{"key":"e_1_3_2_19_1","unstructured":"European Society for Medical Oncology . eUpdate: Hepatocellular carcinoma treatment recommendations. www.esmo.org\/guidelines\/gastrointestinal-cancers\/hepatocellular-carcinoma\/eupdate-hepatocellular-carcinoma-treatment-recommendations"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30937-9"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1717002"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrm1911"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.4161\/cc.7.16.6442"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00109-6"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00163"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0737-6"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01380-3"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01334-9"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919889001"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30146-3"},{"key":"e_1_3_2_32_1","unstructured":"Eisai Inc . An open-label multicenter randomized phase Ib\/II study of E7050 in combination with sorafenib versus sorafenib alone as first line therapy in patients with hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01271504"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000056"},{"key":"e_1_3_2_34_1","unstructured":"Eli Lilly and Company . Phase 2 study of LY2157299 in patients with hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01246986"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3171"},{"key":"e_1_3_2_36_1","unstructured":"Tracon Pharmaceuticals Inc . An open label phase 1B\/2 Trial of TRC105 and sorafenib in patients with hepatocellular carcinoma (HCC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02560779"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1824863"},{"key":"e_1_3_2_38_1","unstructured":"AVEO Pharmaceuticals Inc . A phase 1b\/2 open-label study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03970616"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29496"},{"issue":"11","key":"e_1_3_2_40_1","first-page":"5179","article-title":"A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma","volume":"33","author":"Lee SJ","year":"2013","unstructured":"Lee SJ , LeeJ , SohnIet al. A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res.33(11), 5179\u20135186 (2013).","journal-title":"Anticancer Res."},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.4000"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22201"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23118"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2016.112"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2850-3"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2836-1"},{"key":"e_1_3_2_47_1","unstructured":"Eli Lilly and Company . A Phase 1b\/2 dose escalation and cohort expansion study of the safety tolerability and efficacy of a novel transforming growth factor-beta receptor I kinase inhibitor (galunisertib) administered in combination with anti-PD-1 (nivolumab) in advanced refractory solid tumors (phase 1b) and in recurrent or refractory non-small cell lung cancer or hepatocellular carcinoma (phase 2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02423343"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22063208"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00360"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26731"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.017"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12103025"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.022"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.327"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"e_1_3_2_57_1","unstructured":"US Food and Drug Administration . FDA grants accelerated approval to nivolumab for HCC previously treated with sorafenib (2019). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-nivolumab-hcc-previously-treated-sorafenib"},{"key":"e_1_3_2_58_1","unstructured":"US Food and Drug Administration . FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma (2019). www.fda.gov\/drugs\/fda-grants-accelerated-approval-pembrolizumab-hepatocellular-carcinoma"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz394.029"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01307"},{"issue":"3","key":"e_1_3_2_61_1","first-page":"26","article-title":"Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the randomized, phase III KEYNOTE-240 study","volume":"39","author":"Merle P","year":"2021","unstructured":"Merle P , EdelineJ , BouattourMet al. Pembrolizumab (pembro) vs placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: updated data from the randomized, phase III KEYNOTE-240 study. J. Clin. Oncol.39(Suppl. 3), 268 (2021).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.383"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3094"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.420"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30011-5"},{"key":"e_1_3_2_66_1","unstructured":"BeiGene . RATIONALE-301: a randomized open-label multicenter phase 3 study to compare the efficacy and safety of BGB-A317 versus sorafenib as first-line treatment in patients with unresectable hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03412773"},{"key":"e_1_3_2_67_1","unstructured":"Guoying W . Clinical study of anti-PD-1 antibody camrelizumab in the treatment of recurrent hepatocellular carcinoma after liver transplantation. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04564313"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.267"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.3.1224"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.11.4150"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20140559"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-014-0294-y"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00808"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2021.1972969"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.564"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2571"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.4076"},{"key":"e_1_3_2_80_1","unstructured":"Jiangsu HengRui Medicine Co. Ltd. A randomized open-label international multi-center phase 3 clinical study of PD-1 antibody SHR-1210 plus apatinib mesylate versus sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC) who have not previously received systemic therapy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03764293"},{"key":"e_1_3_2_81_1","unstructured":"Institut f\u00fcr Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest . A phase-II open-label study of pembrolizumab and lenvatinib in patients with advanced stage hepatocellular carcinoma who are refractory to atezolizumab and bevacizumab\/ IO-based therapy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05101629"},{"key":"e_1_3_2_82_1","unstructured":"Bayer . An open-label study of regorafenib in combination with pembrolizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC) after PD1\/PD-L1 immune checkpoint inhibitors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04696055"},{"key":"e_1_3_2_83_1","unstructured":"Exelixis . A randomized controlled phase 3 study of cabozantinib (XL184) in combination with atezolizumab versus sorafenib in subjects with advanced hepatocellular carcinoma who have not received previous systemic anticancer therapy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03755791"},{"key":"e_1_3_2_84_1","unstructured":"Saeed A . A phase I\/II trial of cabozantinib in combination with durvalumab (MEDI4736) with or without tremelimumab in patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies (CAMILLA). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03539822"},{"key":"e_1_3_2_85_1","unstructured":"MD Anderson Cancer Center . A phase II study to evaluate the effects of sequential therapy with the anti c-MET\/VEGFR tyrosine kinase inhibitor (TKI) cabozantinib followed by an anti-PD-1 antibody (nivolumab) in patients with advanced HCC who progressed on first-line therapy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05039736"},{"key":"e_1_3_2_86_1","unstructured":"Institut Bergoni\u00e9 . A phase I\/II study of regorafenib plus avelumab in solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03475953"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1159\/000514420"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2528"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.436"},{"key":"e_1_3_2_90_1","unstructured":"Kelley RK . Multicenter pilot study of the safety efficacy and immune cell profiling in advanced hepatocellular carcinoma (HCC) patients treated with the combination of sorafenib plus nivolumab as first-line of systemic therapy. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03439891"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.4_suppl.513"},{"key":"e_1_3_2_92_1","unstructured":"NYU Langone Health . A phase II randomized controlled trial of nivolumab in combination with BMS-986253 in advanced hepatocellular carcinoma (HCC) patients. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04050462"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2781"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.326"},{"key":"e_1_3_2_95_1","unstructured":"Novartis Pharmaceuticals . A phase Ib\/II open-label multi-center study of INC280 in combination with PDR001 or PDR001 single agent in advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02795429"},{"key":"e_1_3_2_96_1","unstructured":"Eli Lilly and Company . A phase 1b\/2 study of ramucirumab in combination with LY2875358 in patients with advanced cancer.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02082210"},{"key":"e_1_3_2_97_1","unstructured":"Second Affiliated Hospital of Guangzhou Medical University . Donafenib combined with sintilimab for advanced HCC: a single-arm single-center prospective study. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05162352"},{"key":"e_1_3_2_98_1","unstructured":"Suzhou Zelgen Biopharmaceuticals Co. Ltd . A multi-center open dose exploration and dose expansion phase I\/II clinical study of toripalimab (JS001) combined with donafenib in patients with advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04503902"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2020-0283"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1401686"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910836"},{"key":"e_1_3_2_102_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4564"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.269"},{"key":"e_1_3_2_105_1","unstructured":"US Food and Drug Administration . FDA grants accelerated approval to nivolumab and ipilimumab combination for hepatocellular carcinoma (2020). www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-nivolumab-and-ipilimumab-combination-hepatocellular-carcinoma"},{"key":"e_1_3_2_106_1","unstructured":"Bristol-Myers Squibb . A randomized multi-center phase 3 study of nivolumab in combination with ipilimumab compared to sorafenib or lenvatinib as first-line treatment in participants with advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04039607"},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03555"},{"key":"e_1_3_2_108_1","unstructured":"AstraZeneca . A randomized open-label multi-center phase III study of durvalumab and tremelimumab as first-line treatment in patients with advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03298451"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.4_suppl.379"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-1620"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25777"},{"issue":"4","key":"e_1_3_2_112_1","first-page":"3773","article-title":"Expression of TIGIT\/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma","volume":"20","author":"Duan X","year":"2019","unstructured":"Duan X , LiuJ , CuiJet al. Expression of TIGIT\/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma. Mol. Med. Rep.20(4), 3773\u20133781 (2019).","journal-title":"Mol. Med. Rep."},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1249561"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1261779"},{"key":"e_1_3_2_115_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.03.074"},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9520"},{"key":"e_1_3_2_117_1","unstructured":"Gustave Roussy Cancer Campus Grand Paris . A phase I study evaluating safety and efficacy of hepatic intra-arterial administration of ipilimumab in combination with intra-venous nivolumab for advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04823403"},{"key":"e_1_3_2_118_1","unstructured":"BeiGene . A phase 2 randomized open-labeled clinical study investigating the efficacy and safety of ociperlimab in combination with tislelizumab plus BAT1706 and of tislelizumab plus BAT1706 as first-line treatment in patients with advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04948697"},{"key":"e_1_3_2_119_1","unstructured":"Innovent Biologics (Suzhou) Co. Ltd . A randomized open-label controlled multicenter phase III clinical study to compare the effectiveness and safety of IBI310 combined with sintilimab versus sorafenib in the first-line treatment of advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04720716"},{"key":"e_1_3_2_120_1","unstructured":"Innovent Biologics (Suzhou) Co. Ltd . An open-label single-arm Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04401813"},{"key":"e_1_3_2_121_1","unstructured":"Bristol-Myers Squibb . A phase 2 randomized open-label study of relatlimab in combination with nivolumab in participants with advanced hepatocellular carcinoma who are naive to IO therapy but progressed on tyrosine kinase inhibitors (RELATIVITY-073). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04567615"},{"key":"e_1_3_2_122_1","unstructured":"University of Hawaii . Phase II study of TSR-022 (cobolimab) in combination with TSR-042 (dostarlimab) for the treatment of advanced hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03680508"},{"key":"e_1_3_2_123_1","unstructured":"Surface Oncology . A phase 1\/1b study of SRF388 in patients with advanced solid tumors. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04374877"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.10.021"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03362-0"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1973431"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071760"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2021.100606"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1177\/1758835919843463"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0659"},{"key":"e_1_3_2_131_1","unstructured":"Oncolys BioPharma Inc . Phase I study to evaluate the safety and efficacy of telomelysin (OBP-301) in patients with hepatocellular carcinoma. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02293850"},{"key":"e_1_3_2_132_1","unstructured":"CNBG\u2013Virogin Biotech (Shanghai) Ltd . Clinical study of VG161 in subjects with advanced primary liver cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04806464"},{"key":"e_1_3_2_133_1","unstructured":"Guangxi Zhuang Autonomous Region People\u2019s Hospital . Anlotinib for hepatocellular carcinoma (AFHC). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04954521"},{"key":"e_1_3_2_134_1","unstructured":"Genoscience Pharma . Study of GNS561 in patients with liver cancer. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03316222"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-019-05582-x"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1177\/17562848221086126"},{"key":"e_1_3_2_137_1","doi-asserted-by":"publisher","DOI":"10.1039\/D0NR01908A"},{"key":"e_1_3_2_138_1","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-21-274"}],"container-title":["Future Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/fmc-2022-0045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,23]],"date-time":"2024-05-23T19:52:17Z","timestamp":1716493937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/fmc-2022-0045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":136,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["10.4155\/fmc-2022-0045"],"URL":"https:\/\/doi.org\/10.4155\/fmc-2022-0045","relation":{},"ISSN":["1756-8919","1756-8927"],"issn-type":[{"type":"print","value":"1756-8919"},{"type":"electronic","value":"1756-8927"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmc20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}